Infections Due to Acinetobacter baumannii in the ICU: Treatment Options
- 4 June 2017
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 38 (03), 311-325
- https://doi.org/10.1055/s-0037-1599225
Abstract
Bacteria within the genus Acinetobacter (principally A. baumannii-calcoaceticus complex [ABC]) are gram-negative coccobacilli that may cause nosocomial infections in critically ill or debilitated patients (particularly ventilator-associated pneumonia and infections of the bloodstream, urinary tract, and wounds). Treatment of Acinetobacter infections is difficult, as Acinetobacter spp. are intrinsically resistant to multiple antimicrobial agents, and have a remarkable ability to acquire new resistance determinants via mechanisms that include plasmids, transposons, integrons, and resistance islands. Since the 1990s, global resistance to antimicrobials has escalated dramatically among ABC. Global spread of multidrug-resistant (MDR)-A. baumannii strains reflects dissemination of a few clones between hospitals, geographic regions, and continents; excessive use of antibiotics amplifies this spread. Many isolates are resistant to all antimicrobials except colistin (polymyxin E) and tigecycline, and some infections are untreatable with existing antimicrobial agents. Antimicrobial resistance poses a serious threat to treat or prevent infections due to ABC. Strategies to curtail environmental colonization with MDR-ABD will require aggressive infection control efforts and cohorting of infected patients. Thoughtful antibiotic strategies are essential to limit the spread of MDR-ABC. Optimal therapy will likely require combination antimicrobial therapy of existing antibiotics as well as development of novel antibiotic classes.Keywords
This publication has 100 references indexed in Scilit:
- The sensor kinase BfmS mediates virulence in Acinetobacter baumanniiJournal of Microbiology, Immunology and Infection, 2013
- Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infectionsAmerican Journal of Infection Control, 2012
- Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority TrialsClinical Infectious Diseases, 2012
- Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health SystemClinical Infectious Diseases, 2011
- Novel bis-indole agents active against multidrug-resistant Acinetobacter baumanniiDiagnostic Microbiology and Infectious Disease, 2011
- Acinetobacter baumannii 2002–2008: Increase of Carbapenem-Associated Multiclass Resistance in the United StatesMicrobial Drug Resistance, 2010
- Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 resultsDiagnostic Microbiology and Infectious Disease, 2008
- Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistanceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Community-acquired Acinetobacter infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994